{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:34:20Z","timestamp":1791221660051,"version":"4.1.0"},"reference-count":74,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Laboratorios Farmaceuticos Rovi","award":["All the studies mentioned in this manuscript have"],"award-info":[{"award-number":["All the studies mentioned in this manuscript have"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Psychopharmacology"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p>One of the most important challenges in the management of patients with schizophrenia is to ensure adherence to antipsychotic treatment. The contribution of long-acting injectables (LAI) is undeniable in this matter, but there are still some unmet medical needs not covered by these drugs (e.g. quick onset of action for patients with acute exacerbation of schizophrenia). This article summarises the pharmacokinetics, efficacy and safety of Risperidone ISM ( in situ microparticles). The aim of this review is to provide information about the potential uses of this new LAI formulation of risperidone for the treatment of schizophrenia, contextualising and diving into the published evidence. Risperidone ISM shows a rapid release which allows achieving within 12\u2009h risperidone active moiety levels similar to those observed in the steady-state for oral risperidone treatment, achieving a mean average concentration of 38.63\u2009ng\/mL. The plasma concentration of active moiety achieved by Risperidone ISM comes with a predictable dopamine D2 receptor occupancy above 65% throughout the 28-day dosing period, which is accepted as a threshold for the efficacy of the antipsychotic treatment. This can be associated with the positive efficacy findings throughout its clinical development. In the short term, it provides an early and progressive reduction of symptoms in adult patients with acute exacerbation of schizophrenia without the need for loading doses or oral risperidone supplementation, which could contribute to reinforcing the therapeutic alliance between the patient and the psychiatrist. In addition, long-term treatment was effective, safe and well tolerated regardless of the initial disease severity or whether patients were previously treated with Risperidone ISM during an acute exacerbation or switched from stable doses of oral risperidone. Improvement and maintenance of personal and social functioning and health-related quality of life were observed in each setting, respectively. All these findings endorse Risperidone ISM as a useful and valuable treatment for the acute and maintenance management of patients with schizophrenia.<\/jats:p>","DOI":"10.1177\/20451253241280046","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T12:53:52Z","timestamp":1728046432000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Risperidone ISM\n                    <sup>\u00ae<\/sup>\n                    : review and update of its usefulness in all phases of schizophrenia"],"prefix":"10.1177","volume":"14","author":[{"given":"Thomas","family":"Messer","sequence":"first","affiliation":[{"name":"Danuviusklinik GmbH, Pfaffenhofen an der Ilm, Klinik f\u00fcr Psychiatrie, Psychotherapie und Psychosomatik, Akademisches Lehrkrankenhaus der Technischen Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miquel","family":"Bernardo","sequence":"additional","affiliation":[{"name":"Barcelona Clinic Schizophrenia Unit, Hospital Cl\u00ednic de Barcelona, Departament de Medicina, Institut de Neuroci\u00e8ncies (UBNeuro), Universitat de Barcelona (UB), Institut d\u2019Investigacions Biom\u00e8diques August Pi I Sunyer (IDIBAPS), CIBERSAM, ISCIII, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5981-1850","authenticated-orcid":false,"given":"Lourdes","family":"Anta","sequence":"additional","affiliation":[{"name":"Medical Department, Laboratorios Farmac\u00e9uticos ROVI, S.A., Calle Alfonso G\u00f3mez, 45, Madrid 28037, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Mart\u00ednez-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Medical Department, Laboratorios Farmac\u00e9uticos ROVI, S.A., Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"key":"bibr1-20451253241280046","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n1105"},{"key":"bibr2-20451253241280046","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0317"},{"key":"bibr3-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20060"},{"key":"bibr4-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.141"},{"key":"bibr5-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.4.514"},{"key":"bibr6-20451253241280046","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13r08440"},{"key":"bibr7-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10081224"},{"key":"bibr8-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.2076"},{"key":"bibr9-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(21)00039-0"},{"key":"bibr10-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20994"},{"key":"bibr11-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145704004924"},{"key":"bibr12-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00762-0"},{"key":"bibr13-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000139"},{"key":"bibr14-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000203"},{"key":"bibr15-20451253241280046","unstructured":"Okedi EPAR. European medicine agency (EMA), https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/okedi (2022, accessed 25 October 2023)."},{"key":"bibr16-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1994.tb02819.x"},{"key":"bibr17-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.8b00159"},{"key":"bibr18-20451253241280046","first-page":"5","volume":"55","author":"Leysen JE","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"bibr19-20451253241280046","unstructured":"Okedi Summary of Product Characteristics, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/okedi-epar-product-information_en.pdf (2022, accessed 25 October 2023)."},{"key":"bibr20-20451253241280046","volume":"261","author":"Farre M","year":"2011","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"bibr21-20451253241280046","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S332026"},{"key":"bibr22-20451253241280046","first-page":"829","volume":"25","author":"Samtani MN","year":"2011","journal-title":"CNS Drugs"},{"key":"bibr23-20451253241280046","unstructured":"Xeplion summary of product characteristics, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xeplion-epar-product-information_en.pdf (2011, accessed 11 October 2023)."},{"key":"bibr24-20451253241280046","unstructured":"Abilify maintena summary of product characteristics, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/abilify-maintena-epar-product-information_en.pdf (2013, accessed 11 October 2023)."},{"key":"bibr25-20451253241280046","unstructured":"Aristada full prescribing information, https:\/\/www.aristadahcp.com\/downloadables\/ARISTADA-INITIO-PI.pdf (2021, accessed 11 October 2023)."},{"key":"bibr26-20451253241280046","volume":"78","author":"Walling D","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"bibr27-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301242"},{"key":"bibr28-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1016\/j.nsa.2023.103033"},{"key":"bibr29-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1016\/j.nsa.2023.103034"},{"key":"bibr30-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-020-00127-y"},{"key":"bibr31-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"bibr32-20451253241280046","volume-title":"Clinical global impressions, ECDEU assessment manual for psychopharmacology","author":"Guy W","year":"1976"},{"key":"bibr33-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2021.10.698"},{"key":"bibr34-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1037\/0033-2909.112.1.155"},{"key":"bibr35-20451253241280046","volume-title":"8th European conference on schizophrenia research. Virtual conference","author":"Correll C","year":"2021"},{"key":"bibr36-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12526"},{"key":"bibr37-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1016\/j.nsa.2022.100291"},{"key":"bibr38-20451253241280046","volume-title":"Abnormal Involuntary Movement Scale (AIMS), ECDEU assessment manual for psychopharmacology","author":"Guy W.","year":"1976"},{"key":"bibr39-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.154.5.672"},{"key":"bibr40-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"bibr41-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000479"},{"key":"bibr42-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1177\/0269881121996890"},{"key":"bibr43-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1177\/02698811221131992"},{"key":"bibr44-20451253241280046","unstructured":"Risperdal Consta US Package Insert, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/021346s063lbl.pdf (2020; accessed 17 October 2023)."},{"key":"bibr45-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31135-3"},{"key":"bibr46-20451253241280046","unstructured":"Rovi Pharmaceuticals Laboratories. Non-interventional study of Risperidone ISM\n                      \u00ae\n                      in schizophrenia patients hospitalised due to a relapse (RESHAPE). Clinical Trials.gov database, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05480046?term=RESHAPE&draw=2&rank=6 (2022, accessed 25 October 2023)."},{"key":"bibr47-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2021.11.030"},{"key":"bibr48-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1016\/j.nsa.2022.100286"},{"key":"bibr49-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1186\/s12991-023-00464-z"},{"key":"bibr50-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1016\/j.nsa.2022.100285"},{"key":"bibr51-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145711001076"},{"key":"bibr52-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001076"},{"key":"bibr53-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852918001104"},{"key":"bibr54-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2016.01.2118"},{"key":"bibr55-20451253241280046","volume":"65","author":"Vita A","year":"2022","journal-title":"Eur Psychiatry"},{"key":"bibr56-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.20081212"},{"key":"bibr57-20451253241280046","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S198241"},{"key":"bibr58-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2000.tb10933.x"},{"key":"bibr59-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(00)00166-3"},{"key":"bibr60-20451253241280046","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S392351"},{"key":"bibr61-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1097\/00001504-200201000-00006"},{"key":"bibr62-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32833948fa"},{"key":"bibr63-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181dd3103"},{"key":"bibr64-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.116.182683"},{"key":"bibr65-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.177901"},{"key":"bibr66-20451253241280046","doi-asserted-by":"publisher","DOI":"10.3109\/15622975.2012.696143"},{"key":"bibr67-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1177\/0706743717720448"},{"key":"bibr68-20451253241280046","unstructured":"National Institute for Health and Clinical Excellence (NICE). Psychosis and schizophrenia in adults: treatment and management. Clinical Guideline 178, 2014. https:\/\/www.nice.org.uk\/guidance\/cg178"},{"key":"bibr69-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01997-8"},{"key":"bibr70-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20972"},{"key":"bibr71-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-021-00192-x"},{"key":"bibr72-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2022.05.014"},{"key":"bibr73-20451253241280046","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.15032su1"},{"key":"bibr74-20451253241280046","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-018-0734-1"}],"container-title":["Therapeutic Advances in Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20451253241280046","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20451253241280046","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20451253241280046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:53:29Z","timestamp":1777593209000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20451253241280046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":74,"alternative-id":["10.1177\/20451253241280046"],"URL":"https:\/\/doi.org\/10.1177\/20451253241280046","relation":{},"ISSN":["2045-1253","2045-1261"],"issn-type":[{"value":"2045-1253","type":"print"},{"value":"2045-1261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"article-number":"20451253241280046"}}